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Identiﬁcation of KasA as the cellular target
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Phenotypic screens for bactericidal compounds are starting to yield promising hits against
tuberculosis. In this regard, whole-genome sequencing of spontaneous resistant mutants
generated against an indazole sulfonamide (GSK3011724A) identiﬁes several speciﬁc single-
nucleotide polymorphisms in the essential Mycobacterium tuberculosis b-ketoacyl synthase
(kas) A gene. Here, this genomic-based target assignment is conﬁrmed by biochemical
assays, chemical proteomics and structural resolution of a KasA-GSK3011724A complex by
X-ray crystallography. Finally, M. tuberculosis GSK3011724A-resistant mutants increase the
in vitro minimum inhibitory concentration and the in vivo 99% effective dose in mice,
establishing in vitro and in vivo target engagement. Surprisingly, the lack of target engagement
of the related b-ketoacyl synthases (FabH and KasB) suggests a different mode of inhibition
when compared with other Kas inhibitors of fatty acid biosynthesis in bacteria. These results
clearly identify KasA as the biological target of GSK3011724A and validate this enzyme for
further drug discovery efforts against tuberculosis.
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A
fter many years of relatively little attention, Mycobacter-
ium tuberculosis, the causative agent of tuberculosis (TB),
has re-emerged as a priority in the area of neglected
diseases1. The standard 6-month treatment for TB has remained
essentially unchanged over several decades2. Unfortunately, poor
patient compliance and other factors have led to an increasing
prevalence of drug resistance. In 2013, the World Health
Organization (WHO) recorded B480,000 new cases of multi-
drug-resistant (MDR)-TB, resistant to both the front-line drugs,
isoniazid (INH) and rifampicin (RIF)3. Without these two front-
line drugs, MDR-TB generally requires 24 months of treatment
with a variety of second-line antibiotics, which are poorly
tolerated. Due to this continued spread of MDR and
extensively-drug-resistant forms of M. tuberculosis, the WHO
has declared TB as a world health emergency3. Therefore, new
drugs that can complement existing front-line treatment
regimens are urgently required.
In 2013 and updated in 2015, GlaxoSmithKline published a set
of 228 small molecule hits from two phenotypic screening
campaigns against M. tuberculosis4,5. Of those 228 compounds, a
number have been explored via medicinal chemistry for potential
optimization to drug leads and clinical candidates. Phenotypic
screening also offers the opportunity to identify novel biological
targets by molecular mode of action (MoA) studies, which
is generally achieved through a variety of omics-based
technologies6–10. GSK3011724A is a small molecule inhibitor
from the aforementioned 228 phenotypic screening hits4,5. In this
study, we provide an initial proﬁling of GSK3011724A as a
suitable starting point for ‘hit’ to ‘lead’ drug development based
on its in vitro and in vivo characteristics. In addition, through
MoA studies, we identify the M. tuberculosis cellular target of
GSK3011724A to be KasA, a b-ketoacyl synthase. Target
assignment reveals speciﬁcity of GSK3011724A for KasA with a
binding site distinct from other known Kas inhibitors. This
different MoA creates new potential for this recognized target in
future TB drug discovery efforts.
Results
In vitro proﬁling of GSK3011724A. From the outset,
GSK3011724A, an indazole sulfonamide (Fig. 1a), represented an
attractive compound for early stage drug discovery based on its
anti-mycobacterial potency, small size and moderate lipophilicity
(Table 1). Further proﬁling in vitro using standard assays, such as
the hERG ion channel and cytochrome P450 isoforms supported
this view (Table 1). Sensitivity testing of 18 Gram-positive
and Gram-negative bacterial species with GSK3011724A
demonstrated selectivity of this compound for M. tuberculosis. In
addition, GSK3011724A showed negligible activity against a panel
of unrelated proteins (Supplementary Table 1). These desirable
characteristics demonstrated the clear potential of GSK3011724A
as a starting point for medicinal chemistry optimization.
A description of this optimization effort along with a thorough
discussion of the drug development potential and liabilities of this
series will be the subject of a future publication.
In vivo proﬁling of GSK3011724A. GSK3011724A was pro-
gressed into pharmacokinetic (PK) and efﬁcacy experiments to
generate an in vivo proﬁle. Although doses above 400mg kg 1
were not well tolerated by mice, multiple days of dosing up to
300mg kg 1 once daily proceeded with no weight loss or other
adverse effects. The in vivo PK of GSK3011724A in mice was
disproportional based on dosing. At low doses, clearance close to
the liver blood ﬂow rate was observed (in agreement with the
in vitro clearance (Cli) in mouse microsomes), but as the doses
were increased, the maximum concentration (Cmax) and area
under the curve values grew disproportionally (Table 2). This
observation suggests a saturation of the mechanism of clearance,
and may help to explain the reduction in tolerability between 300
and 400mg kg 1 dosing.
The ﬁrst stage of efﬁcacy testing involved an acute model
of infection11. This murine model involved infecting mice
with a high inoculum (105 colony-forming units (c.f.u.)) of
M. tuberculosis H37Rv wild type and beginning treatment the
next day. GSK3011724A (and INH as a positive control) were
administered once daily for 8 days, while the bacilli were in
the exponential growth phase. Despite exhibiting a bacteriostatic
effect in vitro (Supplementary Fig. 1), GSK3011724A
demonstrated a signiﬁcant cidal effect in this murine model
with a B3.5 log c.f.u. reduction relative to untreated controls at
200mg kg 1 (Fig. 1b). The effects of GSK3011724A are similar to
linezolid, which has been shown to be bacteriostatic in vitro12, but
exhibits cidality in vivo11. Importantly, a clear dose–response was
observed, with the ED99 (dose required to reduce bacterial load by
99%) determined as 38mg kg 1. This level of ED99 is only
moderately higher than most of the gold standard TB drugs11.
GSK3011724A (and INH as a positive control) was also
evaluated in a chronic infection assay in which mice were infected
with a lower inoculum of M. tuberculosis H37Rv (102 c.f.u.) and
left untreated for 6 weeks, allowing the bacilli to reach a steady
state. GSK3011724A was then dosed daily for 2 months. The
dose–response curve in this chronic assay was shifted to higher
doses than in the acute model, but the targeted 42 log c.f.u.
reduction was achieved at 100mg kg 1 for GSK3011724A,
producing a 2.4 log c.f.u. reduction (Fig. 1c). These data clearly
establish GSK3011724A as an active compound in both the acute
and chronic in vivo murine models of M. tuberculosis infection.
Importantly, if GSK3011724A were demonstrated to inhibit an
unexploited potential antimicrobial target, these data would
provide a signiﬁcant level of validation and conﬁdence for further
exploration of that target for TB drug discovery.
GSK3011724A target identiﬁcation. A fundamental strategy in
drug discovery is establishing the MoA of inhibitory compounds.
Following the identiﬁcation and validation of the molecular
target, target-speciﬁc optimization of the compound can be
pursued to improve efﬁcacy and reduce toxicity. Due to the
recent successes of utilizing whole-genome sequencing (WGS)
of spontaneous resistant mutants as a primary step in the
elucidation of the target of phenotypic hits6,7,9, this methodology
was used to establish the target of GSK3011724A.
The minimum inhibitory concentration (MIC) of
GSK3011724A in Mycobacterium bovis Bacillus Calmette–Gue´rin
(BCG) was determined to be 0.5 mM. Spontaneous resistant
mutants were initially generated usingM. bovis BCG at 5 , 10
and 20 the MIC of GSK3011724A, with frequencies of
resistance (FoR) of 12 10 8, 3 10 8 and 2 10 8, respec-
tively. The FoR was subsequently determined against M.
tuberculosis at 2.5 mM (10 MIC of GSK3011724A on solid
media, 0.25 mM) giving a frequency of 9.5 10 7. This FoR is
slightly higher than normally desired but is lower than that
of INH.
From the total of 17 M. bovis BCG spontaneous resistant
mutants generated, eight were selected for WGS. Six of the eight
M. bovis BCG mutants were found to possess a number of high-
quality (statistically relevant) single-nucleotide polymorphisms
(SNP) compared with the sequenced wild-type reference strain
(Genbank accession number NC_008769.1), all of which located
to the gene annotated kasA, encoding an essential b-ketoacyl
synthase involved in mycolic acid biosynthesis13 (Table 3). The
data offered the ﬁrst evidence that KasA is the target of
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GSK3011724A, providing a starting point for validation studies.
Subsequently, instead of using WGS, the kasA gene from 12
isolated M. tuberculosis resistant mutants was speciﬁcally
sequenced following ampliﬁcation by PCR. The data conﬁrmed
the results from M. bovis BCG, with eleven of the twelve mutants
showing SNPs in kasA (Table 3). The WGS results of the two
remaining M. bovis BCG mutants did not reveal SNPs of a high
frequency; no gene contained a SNP of greater than 50%
frequency, corresponding to the percentage of SNP in the cell
population from which the genomic DNA was prepared.
KasA target validation. Following the target identiﬁcation of
KasA by WGS, a variety of techniques were utilized to conﬁrm
its role as the biological target of GSK3011724A. Firstly, the
inhibition of mycolic acid biosynthesis by GSK3011724A was
investigated. M. bovis BCG was labelled using [14C]-acetate and
treated with increasing concentrations of GSK3011724A, with
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Figure 1 | The anti-tubercular activity of GSK3011724A. (a) Chemical structure of GSK3011724A. (b,c) GSK3011724A was evaluated in an acute (b) and
chronic (c) model of murine TB infection. Each symbol represents data from a single mouse. A two-fold log c.f.u. reduction equates to a 2 log c.f.u.
difference compared with untreated mice at the end of the treatment period. Untreated mice gave a log c.f.u. count of 7.1±0.1 (mean±s.d., n¼ 5 mice) in
the acute assay and 5.8±0.26 (mean±s.d., n¼ 7 mice for the INH experiment) or 6.0±0.5 (mean±s.d., n¼ 5 mice for GSK3011724A experiment) in the
chronic assay. (d) Comparison of the in vivo efﬁcacy of GSK3011724A and INH against M. tuberculosis H37Rv wild-type (H37Rv WT) and M. tuberculosis
KasA mutant strains. Mice were infected with each strain and administered with INH or GSK3011724A at different doses during the acute phase (days 1 to
8 after infection). Each dot represents data from a single mouse. Log c.f.u. counts are shown as the difference with respect to the untreated group infected
with each strain (Dlog c.f.u. for each mouse).
Table 1 | In vitro proﬁle of GSK3011724A.
Assay Value
MIC H37Rv 0.8mM
HepG2 IC50 4100mM
ChromLogD7.4 3.8
Kinetic Solubility 4550 mM
hERG IC50 450mM
CYP3A4 IC50 440mM
CYP1A2 IC50 450mM
CYP2C9 IC50 12.6mM
CYP2D6 IC50 450mM
18 Gram-positive and Gram-negative species 4128mgml 1
Plasma protein binding (mouse) 76.9%
Plasma protein binding (human) 91.8%
Cli (mouse) 6.1mlmin 1 g 1
Cli (human) 0.95mlmin 1 g 1
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INH and the KasA inhibitor thiolactomycin (TLM) used as
positive controls. Following drug treatment, the total fatty acid
methyl esters (FAMEs) and a-mycolate and keto-mycolic acid
methyl esters (a- and k-MAMEs) were extracted and analysed by
autoradiography thin-layer chromatography (TLC). As shown in
Fig. 2a (left panel) there was a clear visual dose-dependent
reduction in the production of a-MAMEs and k-MAMEs upon
treatment with GSK3011724A. This characteristic proﬁle of total
MAMEs inhibition and FAMEs accumulation mirrors the known
fatty acid synthase (FAS)-II inhibitors TLM and INH (Fig. 2a,
middle panel). When spots were excised from the TLC and
quantiﬁed by scintillation counting (Table 4), GSK3011724A at
4 MIC in comparison to the non-treated control produced a
55.2% and 42.3% reduction in a-MAMEs and k-MAMEs,
respectively. In contrast, quantiﬁcation of the levels of FAMEs
increased by 186.5% at 4 MIC. When compared with the
known KasA inhibitor TLM, GSK3011724A at 1 MIC afforded
a similar level of inhibition of a-MAMEs and k-MAMEs, and an
increase in FAMEs synthesis, respectively (Table 4). A slightly less
pronounced effect at their relative MICs was observed for INH in
comparison to GSK3011724A (Table 4). The inhibition of
mycolic acid biosynthesis by GSK3011724A was even more
apparent when cell wall-bound a- and k-MAMEs were analysed,
with an almost visual complete inhibition in a dose-dependant
manner, which was similar to INH and TLM (Fig. 2a, right
panel). To investigate whether GSK3011724A affects the synthesis
of other mycobacterial lipids, addressing the potential of
additional cell wall-associated targets, the total cellular lipids (and
fractionated apolar lipids and polar phospholipids) were extracted
and analysed following drug treatment. Firstly, a decrease in
trehalose dimycolate (TDM), trehalose monomycolate (TMM)
and glycerol monomycolate was observed with GSK3011724A
(and TLM and INH), consistent with inhibition of mycolic acid
biosynthesis (Fig. 2b; Table 4 and Supplementary Fig. 2a).
Secondly, no signiﬁcant differences were observed in lipid
composition when apolar lipids and polar phospholipids were
analysed by autoradiography-TLC (Supplementary Fig. 2a,b),
suggesting that GSK3011724A does not target other lipid
biosynthetic pathways, and is speciﬁc for KasA.
To further corroborate that GSK3011724A inhibits mycolic
acid biosynthesis and, more speciﬁcally, targets KasA, the impact
on the MIC was investigated using strains of M. bovis BCG
overexpressing components of FAS-II. The mycobacterial expres-
sion vectors, pMV261 containing M. tuberculosis kasA14, kasB14,
fabH15, inhA16, hadABC17 and mabA16, were electroporated into
M. bovis BCG and growth analysed at a concentration range with
respect to the MIC of GSK3011724A (Fig. 2c). M. bovis BCG
containing the pMV261 empty vector exhibited no change in
sensitivity to GSK3011724A compared with the wild-type
untransformed strain, with an MIC of 0.5 mM (Fig. 2c). This
Table 2 | In vivo pharmacokinetic proﬁle of GSK3011724A.
Target dose (mg kg 1) Cmax (ngml 1) Cmax/Dose ngml 1 (mg kg 1) tmax (h) AUC0-t (ng hml 1) DNAUC nghml 1 (mg kg 1)
10* 917±279 84.7±21.5 0.25–0.75 1099±152 104±19.1
25 1392±424 63.9±19.4 0.5 2279±581 107±27.3
50 12500±153 250±23.1 0.25–1.0 32549±3009 667±64.2
100 10570±572 120±6.49 0.75–1.0 57179±7559 667±57.2
200 33000±7017 165±35.1 2.0 251437±37054 1272±188
AUC, area under the curve; Cmax, maximum concentration measured; DNAUC, dose-normalized area under the curve.
Pharmacokinetic parameters estimated for GSK3011724A after a single oral gavage administration to female C57BL/6J mice (n¼ 3) at different doses. Mice dosed above 400mgkg 1 were withdrawn
after the second administration of GSK3011724A due to poor clinical status. Standard deviation (s.d.) of the mean is also included.
*Mean and s.d. values calculated from n¼ 3 mice.
Table 3 | Sequencing of spontaneous resistant mutants identiﬁes SNPs in kasA.
Organism Mutant Frequency of SNP Genome position of SNP Base change Amino-acid substitution
M. bovis BCG 1 75% 2497100 aCc/aGc T114S
2.44% 2497376 cCc/cTc P206L
2 100% 2497142 cTg/cCg L128P
3 100% 2497373 cTg/cCg L205P
4 100% 2497376 cCc/cTc P206L
5 100% 2497195 Atg/Gtg M146V
6 100% 2497589 aTg/aCg M277T
M. tuberculosis 1 — 2518524 gTg/gCg V137A
2 — 2518524 gTg/gYg V137A/V
3 — 2518524 gTg/gCg V137A
4 — 2518524 gTg/gCg V137A
5 — 2518715 Ccc/Tcc P201S
6 — 2518715 Ccc/Tcc P201S
7 — 2518715 Ccc/Tcc P201S
8 — 2518715 Ccc/Tcc P201S
9 — 2518943 Atg/Gtg M277V
10 — 2518944 aTg/aCg M277T
11 — 2519327 Ggc/Agc G405S
SNP, single-nucleotide polymorphism.
WGS and sequencing of kasA from GSK3011724A-resistant mutants of M. bovis BCG and M. tuberculosis, respectively, revealed kasA-speciﬁc mutations. For the WGS of M. bovis BCG mutants, the
frequency of SNP is shown. This corresponds to the percentage of SNP in the cell population from which the genomic DNA was extracted. The kasA SNP frequency in the M. tuberculosis mutants cannot
be deduced due to the method of analysis used. The genomic location of the mutations is stated. The missense mutations are represented in codons, where the capital letter identiﬁes the base change.
The ‘Y’ indicates a mixed population of ‘C’ or ‘T’ bases. The resulting amino-acid substitutions are listed.
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Figure 2 | Inhibition of mycolic acid biosynthesis by GSK3011724A. (a) M. bovis BCG cultures, labelled with [14C]-acetate, were treated with
GSK3011724A, TLM and INH. The total FAMEs and MAMEs were extracted and analysed by autoradiography-TLC using equal counts (25,000 c.p.m.) for
each lane, respectively (left and middle panels). In addition, cell wall-bound MAMEs were isolated and an equal aliquot (5%) was analysed by
autoradiography-TLC for each lane, respectively (right panel). (b) M. bovis BCG total cellular lipids containing TDM/TMM were extracted following
labelling and drug treatment (GSK3011724A, TLM and INH) and analysed by autoradiography-TLC using equal counts (25,000 c.p.m.) for each lane,
respectively. (c) Impact on the MIC of GSK3011724A upon the overexpression of members of FAS-II in M. bovis BCG. The overexpression constructs of
M. tuberculosis enzymes (Mt) pMV261-Mt-kasA, pMV261-Mt-kasB, pMV261-Mt-fabH, pMV261-Mt-inhA, pMV261-Mt-hadABC and pMV261-Mt-mabAwere
electroporated intoM. bovis BCG and the MIC of GSK3011724A was evaluated with reference toM. bovis BCG pMV261. The outer and inner spots represent
103 and 102 cells plated, respectively.
Table 4 | Quantiﬁcation of inhibition of mycolate containing products by GSK3011724A.
Inhibitor Inhibitor
concentration
(lM)
FAMEs a-MAMEs k-MAMEs TDM TMM
c.p.m. % Relative
to control
c.p.m. % Relative
to control
c.p.m. % Relative
to control
c.p.m. % Relative
to control
c.p.m. % Relative
to control
Control 0 9,796 100 4,029 100 7,641 100 3,149 100 1,425 100
GSK3011724A 0.25 16,207 165 3,438 85 7,147 94 ND ND ND ND
0.5 17,780 182 3,026 75 6,651 87 864 27 911 64
1 16,478 168 2,488 62 4,925 64 874 28 893 63
2 18,268 186 1,806 45 4,407 58 ND ND ND ND
4 ND ND ND ND ND ND 652 21 951 67
Control 0 10,231 100 4,156 100 6,722 100 —* —* —* —*
TLM 95 15,334 150 2,721 65 3,727 55 817 26 704 49
INH 1.5 16,926 165 1,426 34 1,808 27 642 20 552 39
a-MAMEs, a-mycolate acid methyl esters; FAMEs, fatty acid methyl esters; INH, isoniazid; k-MAMEs, keto-mycolic acid methyl esters; ND, not determined; TDM, trehalose dimycolate;
TLM, thiolactomycin; TMM, trehalose monomycolate.
Quantiﬁcation of [14C]-labelled products were determined by excising spots directly from TLC plates (Fig. 2a, left and middle panels, and Fig. 2b) and subjecting them to scintillation counting using 10ml
of EcoScintA.
*Control values as reported above.
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was also apparent for the pMV261 constructs containing kasB,
inhA, fabH, hadABC and mabA (Fig. 2c). However, ample growth
of the KasA overexpressor strain was observed at 4mM, indicating
an increase in resistance, and a MIC shift of 48 (Fig. 2c),
providing further evidence to support KasA as the cellular target
of GSK3011724A.
Previous studies have reported KasA activity in an in vitro
condensing assay using puriﬁed recombinant proteins18. This
assay was replicated to demonstrate the speciﬁc inhibition of
KasA by GSK3011724A. Initially, FabD was used to generate
[14C]-malonyl-AcpM from holo-AcpM and [14C]-malonyl-CoA.
KasA, in the absence or presence of GSK3011724A, elongated
C16-AcpM in a condensation reaction with [14C]-malonyl-AcpM.
Treatment with 1mM of GSK3011724A provided a 58.5%
inhibition of KasA activity (based on triplicate data,
Supplementary Fig. 3).
To investigate whether GSK3011724A exerts its effect by
directly binding to KasA, we employed a chemoproteomics
strategy19,20. A tagged analogue (1) with an MIC of 49 mM was
generated, which was covalently linked to Sepharose beads
(Fig. 3a). The tagged analogue-(1)-derivatized beads were
incubated with M. bovis BCG extracts, in the absence or
presence of an excess of unbound GSK3011724A. In this
competition-binding format, target proteins would be expected
to bind to the beads predominantly in the absence of
excess competing compound. After washing of the beads,
bound proteins were digested with trypsin and subjected
to quantitative mass spectrometry. Among 42,000 proteins
identiﬁed, only three proteins were efﬁciently competed off the
beads by excess GSK3011724A: KasA, and, to a lesser degree, the
non-essential polyketide synthases Pks10 and Pks11 (refs 21,22;
Fig. 3a; Supplementary Data 1 and 2). The experiment was
repeated in a concentration-dependent format to determine half-
maximal inhibition (IC50) values that refer to the concentration of
compound (GSK3011724A) required to competitively block 50%
of the target (that is, KasA) from binding to the beads (Fig. 3b;
Supplementary Data 3 and 4). These IC50 values are a measure of
target afﬁnity, but are also affected by the afﬁnity of the target for
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Figure 3 | Chemoproteomics proﬁling of GSK3011724A. (a) A propylamine-tagged derivative of GSK3011724A (1, inset) was synthesized and covalently
immobilized to NHS-activated sepharose. Beads were incubated with M. bovis BCG extract either in the presence of vehicle (DMSO) or GSK3011724A
(10mM, 40 mM). Proteins captured by the beads in both conditions were quantiﬁed by LC–MS/MS analysis. KasA, Pks10 and Pks11 were identiﬁed as
potential targets of GSK3011724A by virtue of their reduced capturing in the presence of excess GSK3011724A. (b) Generation of IC50 values for KasA,
Pks10 and Pks11. The chemoproteomic experiment was performed as in a but over a range of concentrations of the competing ‘free’ inhibitor GSK3011724A
(2–0.003mM for KasA, 40–0.16mM for Pks10 and Pks11) and a structurally related inactive analogue, 2 (40–0.16mM). Apparent dissociation constants for
GSK3011724A were determined from two independent experiments.
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the bead-immobilized ligand. The latter effect can be deduced by
measuring the depletion of the target proteins (KasA, Pks10 and
Pks11) by the beads. Thus, apparent dissociation constants
(Kdapp) can be determined, which are largely independent from
the bead ligand19,23. The Kdapp value was determined as 9 nM for
KasA, suggesting a high level of afﬁnity for the enzyme. In
excellent agreement with these chemoproteomic afﬁnities, direct
binding of GSK3011724A to puriﬁed KasA was also determined
using surface plasmon resonance (SPR) and found to be in the
10–20 nM range (Supplementary Fig. 4). A much weaker
apparent dissociation constant was observed for both Pks10
and Pks11 (Kdapp 1.4 mM). In addition, we compared the results
of the active compound GSK3011724A with a structurally related
inactive analogue 2 (MIC4125 mM). The Kdapp for this inactive
molecule was determined to be 4.5 mM for KasA, which
corresponds to a B490-fold window for KasA between active
and inactive compound. There was no binding observed for
Pks10 and Pks11 by the inactive analogue 2 (Fig. 3b;
Supplementary Data 5).
To evaluate the potential of GSK3011724A for interaction with
human proteins, which could represent off-targets relevant for
drug safety, we performed a similar set of chemoproteomics
experiments with a human protein extract, generated by
combining detergent (NP40) lysates from HEK293 cells, K562
cells and placenta tissue (Supplementary Data 6). Only a single
protein showed moderate competition by GSK3011724A, NQO2,
with an apparent dissociation constant of 4–6 mM. NQO2 is an
off-target of many small molecules drugs24. Other potential
off-targets may exist that are not expressed in the cells and tissues
used for the proﬁling, and the compound may exhibit binding
modes, which are inconsistent with its immobilization. However,
taken together, the chemoproteomics data demonstrate that
GSK3011724A is a highly potent and selective inhibitor of KasA
with no discernible off-targets in the above human cell lines and
placenta tissue.
Analysis of the KasA-GSK3011724A co-crystal structure.
Curious to understand the molecular details of GSK3011724A
binding to KasA, a 2.13Å co-crystal structure of the dimeric
KasA-GSK3011724A complex was solved (Table 5). All literature
inhibitors to date, such as TLM, reside in the malonyl
substrate pocket close to the catalytic Cys171 residue25,26
(Fig. 4a). However, computational docking studies to place
GSK3011724A into this site produced puzzling binding modes,
which did not explain the roles of the key molecular features of
GSK3011724A. The co-crystal structure reveals that, in contrast
to TLM, GSK3011724A uniquely binds within the large acyl
channel that normally accommodates the growing meromycolic
acid chain, unexpectedly trapping the open conformation of the
enzyme (Fig. 4a). GSK3011724A sits at the branch point of the
acyl channel, a feature thought to confer speciﬁcity for ‘kinked’
unsaturated substrates. Within this site, density for a long linear
molecule, modelled as polyethylene glycol (PEG), is also
consistently present and perfectly complements the space
between the compound and the protein (Fig. 4b). This
sandwich of PEG and GSK3011724A enables the large acyl
cavity to be ﬁlled, occupying the volume of the branched
phospholipid chains previously observed within this pocket25.
From the co-crystal structure, the structure–activity relation-
ship of GSK3011724A is evident (Fig. 4b,c). The indazole ring lies
across the ﬂat hydrophobic surface formed by residues such as
Gly200 and Pro201, and the amide of the sulfonamide makes a
key hydrogen bond with Glu199. This anchors the ligand in an
ideal position, allowing the kink (introduced by the sulfonamide
linkage) to place the butyl chain into an orthogonal narrow
lipophilic channel lined by residues such as Ile347, Ile202 and
Phe239.
The resistance-conferring mutations observed in Table 3 can be
readily rationalized by the inhibitor binding site and MoA of
GSK3011724A (Fig. 5a). Pro201 and Pro206 both lie within the
acyl site and are in direct contact with the ligand (Fig. 5b).
Exchange of proline for a hydrophilic serine residue (Pro201Ser)
disfavours interactions with the aromatic indazole ring, whereas
the Pro206Leu substitution introduces steric crowding of the
ligand. The remaining mutations are found away from the
inhibitor site, in regions likely to inﬂuence the conformational
equilibrium and ease of transition between the closed and open
state required for GSK3011724A inhibition. The a5 to a6 helix-
turn-helix (HTH) arm of one KasA monomer, comprising of
residues 115–145, must slide past its dimer counterpart (a05–a06)
and the a02 helix as the acyl cavity opens. Mutations Leu128Pro,
Val137Ala, Met146Val and Leu205Pro are either within the HTH
motif or the a2 helix and undergo substantial movement to the
open form (Fig. 5c). Met277 also lies at the dimer interface,
however, its position is ﬁxed between the two states. This residue
could be considered as the ‘ball’ in a ‘ball and socket’ joint around
which the a5–a6 HTH pivots (Fig. 5d). Reducing the size of
Met277 to valine may alter the movement and position of the
HTH. Similarly, Thr114 sits at another ﬁxed pivot point, the start
of the ﬁrst helix of the HTH (Fig. 5d). The positioning of Thr114
breaks the b-strand that proceeds it and anchors the HTH arm to
its opposite b-strand partner Val198 via two hydrogen bonds
(through a carbonyl-backbone interaction and by the interaction
of the threonine side chain hydroxyl to the carbonyl of Val198)
(Fig. 5e). The Thr114Ser resistance-conferring mutation would
introduce more ﬂexibility and may reduce the anchoring stability
needed in this position.
Table 5 | Data collection and reﬁnement statistics.
X-ray diffraction data KasA/GSK3011724A
Data collection
Space group P31
Cell dimensions
a, b, c (Å) 77.34, 77.34, 147.68
a, b, g () 90.000, 90.000, 120.000
Resolution (Å) 66.98–2.13(2.38–2.13)
Rmerge 0.053 (0.474)
ccI1/2 0.998 (0.822)
I/sI 16.9 (3.0)
Completeness (%) 98.6 (97.3)
Redundancy 4.3(4.0)
Wilson B-factor 34.16
Reﬁnement
Resolution (Å) 66.98–2.13
No. reﬂections 235866 (60834)
No. uniq reﬂections 54699 (15385)
Rwork/ Rfree 0.162/0.186
No. atoms 6470
Protein 6041
Ligand/ion 36/28
Water 365
B-factors
Protein 39.70
Ligand/ion 39.90/48.61
Water 43.92
R.m.s.d.
Bond lengths (Å) 0.0044
Bond angles () 0.8045
Twin fraction 0.39
Values in parentheses are for the highest-resolution shell. Collection based on a single crystal.
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In summary, these crystallographic insights complete a
consistent picture of the molecular MoA of this inhibitor and
provide a platform for rational optimization of the GSK3011724A
scaffold as well as de novo structure-based drug design. Excitingly,
this offers a fresh opportunity to target KasA at a site distinct
from previous inhibitors and one that is able to achieve selectivity
over other related b-ketoacyl synthases (FabH and KasB)
involved in fatty acid biosynthesis, as key residues required for
afﬁnity are not conserved (Fig. 5f,g).
In vivo target engagement of GSK3011724A and KasA.
Although the evidence presented above provided a high level of
conﬁdence that KasA was the true biological target of
GSK3011724A, there was still a need to conﬁrm that target
engagement was responsible for the potent in vivo activity. A
selection of the M. tuberculosis spontaneous resistant mutants
isolated against GSK3011724A were tested for their growth pro-
ﬁle in mice using the acute model11 (Fig. 1d). While the two
mutants showed an attenuated growth rate in untreated animals,
their response to INH treatment remained essentially unchanged.
Given the close relationship between KasA and InhA, the INH
data were particularly signiﬁcant, conﬁrming that the observed
resistance in vivo was not merely an artefact of the limited growth
rate. In contrast with INH, the response with GSK3011724A
against both strains with mutations mapping to kasA showed
clear signs of resistance (Fig. 1d). Mutation Met277Thr appeared
to impart complete resistance up to the maximum dose tested
(140mg kg 1), while mutation Pro201Ser gave a lesser response
at 100mg kg 1. These results support the MIC shifts observed
in vitro and furthermore provide a critical link between the target
identiﬁcation and in vivo validation of KasA.
Discussion
On-going efforts to combat drug-resistant TB have taken
many forms including the re-purposing of broad spectrum
antibacterials, target-based programs on mycobacterial enzymes,
efforts to optimize or re-invent known TB drugs (like INH and
RIF), and phenotypic screening approaches, which have all been
widely reported4,27–32. In this work, through a variety of in vitro
and in vivo experiments, a new chemical scaffold, exempliﬁed by
GSK3011724A, has been identiﬁed to speciﬁcally target an
integral component of mycolic acid biosynthesis, KasA (ref. 18).
Mycolic acids are unique and fundamental components of the
mycobacterial cell wall and KasA is essential in M. tuberculosis13.
Mycolic acid biosynthesis involves two distinct fatty acid
synthesis pathways. The FAS-I system is required for de novo
fatty acid synthesis, where a single, multifunctional polypeptide
generates short chain fatty acyl-CoA esters. FabH, a b-ketoacyl
ACP synthase, forms a pivotal link between FAS-I and FAS-II,
condensing C14-CoA (generated by FAS-I) and malonyl-AcpM
producing C16-AcpM (ref. 15). This product is channelled to
KasA of the FAS-II system33. The FAS-II system is comprised of
four enzymes acting in a consecutive cycle: KasA and KasB,
condensing enzymes18; MabA, a keto-reductase34; HadABC, a
dehydratase35; and InhA, an enoyl-reductase36. The FAS-II
system enables fatty acid elongation leading to meromycolic
acids (C56), which are then condensed with C26-CoA (from
FAS-I) by the polyketide synthase Pks13 (refs 37,38), followed by
reduction, culminating in the production of mature mycolic
acids39. The lipidomics experiments showing accumulation of
FAMEs and depletion of MAMEs conﬁrms that GSK3011724A
speciﬁcally inhibits FAS-II and mycolic acid biosynthesis
(Fig. 2a,b; Table 4; Supplementary Fig. 2).
Inhibitors of KasA have been reported in the literature14,40,41.
Most notable among these is TLM, which is known to inhibit all
three mycobacterial Kas enzymes: KasA, KasB and FabH14,15.
Interestingly, GSK3011724A, unlike TLM and other Kas
inhibitors, whether against M. tuberculosis or other bacteria (via
FabH, FabB and FabF), displayed unique speciﬁcity, targeting only
KasA (Fig. 2c). An explanation of this ﬁnding comes from close
inspection of the GSK3011724A-KasA complex crystal structure,
where speciﬁc changes in the acyl pockets of the related enzymes
disfavour the unique binding mode of GSK3011724A (Figs 4
and 5). For example, the Gly200Arg and Pro201Thr changes from
KasA to KasB no longer allow the indazole ring to sit favourably in
the acyl pocket of KasB (Fig. 5f). This offers an explanation as to
why the WGS data did not result in the identiﬁcation of SNPs in
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Figure 4 | X-ray crystallographic analysis of KasA complexed with GSK3011724A. (a) Co-crystal structure of KasA dimer (yellow, blue) with
GSK3011724A (green space ﬁlled) and PEG (green sticks) bound with the open conformation of the acyl channel. The active site cysteine C171 is shown in
line format, as are an overlay of the TLM and a phospholipid ligand taken from PDB entry 4C72 (ref. 25). (b) GSK3011724A and PEG both shown in stick
format ﬁlling the acyl channel. (c) Hydrogen bonds between GSK3011724A and E199 within the binding site.
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KasB and why the resistance mutations in KasA often map to
points of variation amongst the Kas enzymes.
Importantly, GSK3011724A, despite representing an un-
optimised screening hit, gives at least one order of magnitude
greater potency relative to the most studied KasA inhibitor, TLM,
and its favourable PK properties allowed for the critical in vivo
experiments described in this work. The data obtained from
murine assays (both acute and chronic infection) exemplify the
credible potential of KasA inhibitors to give signiﬁcant efﬁcacy
and, to our knowledge, offer the ﬁrst in vivo validation of KasA as
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a drug target (Fig. 1d). Together with the promising drug-like
proﬁle of GSK3011724A, these data provide signiﬁcant con-
ﬁdence for the future exploration of KasA as a drug target,
inhibitors of which could become key players in the development
of new anti-tubercular drugs and will be explored in a future
publication.
Methods
Synthetic and characterization details for the compounds and the SPR experiment
described herein can be found in Supplementary Methods. All animal studies were
ethically reviewed and carried out in accordance with European Directive 2010/63/
EU and the GSK Policy on the Care, Welfare and Treatment of Animals. The
human biological samples were sourced ethically and their research use was in
accordance with the terms of informed consent.
Assessment of acute and chronic efﬁcacy in murine TB models. INH
was purchased from Sigma-Aldrich and prepared freshly in distilled water.
GSK3011724A was prepared freshly in 1% aqueous methylcellulose. The assess-
ment of the chronic and acute efﬁcacy in murine TB models was performed using
speciﬁc pathogen-free, 8–10 week-old female C57BL/6 mice purchased from
Harlan Laboratories and allowed to acclimate for 1 week and kept under controlled
conditions in a P3 high-security facility with unlimited sterile food and water.
In the acute model11, mice were intratracheally infected with M. tuberculosis
H37Rv wild-type (H37Rv WT) 100,000 c.f.u. for each mouse, and lungs harvested
on day 9. GSK3011724A and INH were administered daily for 8 consecutive days,
starting on day 1 after infection. In the chronic model42, mice (n¼ 2 mice at each
dose level) were intratracheally infected with 100 c.f.u. for each mouse; INH or
GSK3011724A was administered daily for 8 consecutive weeks, starting 6 weeks
after infection. Lungs were harvested 24 h after the last administration in both
assays. All lung lobes were aseptically removed, homogenized and frozen.
Homogenates were unfrozen and plated in 10% OADC-7H11 medium
supplemented with activated charcoal (0.4%) and grown for 18–25 days at 37 C.
Non-linear ﬁtting was performed with the dose–response data (log c.f.u. versus
dose) and the dose in mg kg 1 that reduced lung bacterial burden by 99% with
respect to untreated mice was estimated (ED99). Mice were supervised every day
under a protocol paying attention to weight loss, apparent good health (bristled
hair and wounded skin) and behaviour (signs of aggressiveness or isolation).
Animals were euthanized by CO2 inhalation.
MIC determination and resistant mutant generation. M. bovis BCG strain
Pasteur and derivatives were cultured at 37 C and 5% CO2 in static liquid or solid
medium. Liquid medium contained Middlebrook 7H9 (Difco) supplemented with
0.05% (v/v) Tween-80, 10% (v/v) Middlebrook ADC and 0.25% (v/v) glycerol.
Solid medium contained Middlebrook 7H11 agar (Difco) with 10% (v/v)
Middlebrook OADC and 0.5% (v/v) glycerol. Where applicable, 25 mgml 1
Kanamycin was added to the liquid or solid media to select for mycobacterial
plasmids. The constructs pMV261, pMV261-Mt-kasA, pMV261-Mt-kasB,
pMV261-Mt-fabH, pMV261-Mt-inhA, pMV261-Mt-hadABC and pMV261-Mt-
mabA were electroporated into M. bovis BCG14–17. Wild-type M. bovis BCG
electrocompetent cells were prepared by pelleting a mid-log culture and washing
with decreasing volumes of ice-cold 10% (v/v) glycerol. The cells were incubated on
ice with 1 mg plasmid DNA before being transferred to a 0.1 cm electrode-gap
electroporation cuvette and subjected to a single pulse of 1.8 kV. Cells were
recovered in liquid media overnight at 37 C and selected on solid medium
containing the appropriate antibiotic.
The MIC of GSK3011724A was determined by plating 104, 103, 102 and
101 cells from a mid-log culture of M. bovis BCG on solid medium containing
increasing concentrations of compound in a dose–response format. The MIC was
deﬁned as the concentration of compound that caused complete inhibition of
bacterial growth. M. bovis BCG and M. tuberculosis spontaneous resistant mutants
were generated by plating 108 cells from a mid-log phase culture on solid media
containing either 5 , 10 or 20 MIC of GSK3011724A. Potentially resistant
colonies were inoculated into liquid media, cultured to mid-log growth phase,
and selected on solid media containing 5 MIC of GSK3011724A to conﬁrm
phenotypic resistance. The MIC of the resistant M. tuberculosis mutant strains
against GSK3011724A was determined either using the MABA resazurin assay43 or
by serial dilution and agar plating.
Sequencing of resistant mutants. Wild-typeM. bovis BCG and theM. bovis BCG
GSK3011724A-resistant mutants were characterized by WGS6,9. Brieﬂy, puriﬁed
genomic DNA was prepared for sequencing using the Nextera DNA Sample
Preparation Kit (Illumina). The DNA libraries were puriﬁed and quantiﬁed using
Agencourt AMPure XP beads (Beckman Coulter Genomics) and Quant-iT
PicoGreen dsDNA kit (Life Technologies), respectively. Fragment sizes were
determined using an Agilent Technologies 2100 Bioanalyzer with a High Sensitivity
DNA chip. Following the MiSeq preparation guide, the libraries were sequenced on
a MiSeq Benchtop Sequencer using the MiSeq Reagent Kit v2, 300 cycles. Reads
were aligned to the reference genome M. bovis BCG Pasteur 1173P2 (accession:
NC_008769.1).
The kasA gene (Rv2245) from M. tuberculosis GSK3011724A-resistant mutants
was sequenced speciﬁcally. The gene was ampliﬁed by PCR using 0.5 mM of the
ﬂanking primers 50-aggacaagtacggcgtcaag (forward) and 50-gtaaccagctccgtcattg
(reverse). The ampliﬁcation was performed with 0.02U ml 1 of KOD Xtreme Hot
Start DNA Polymerase (Merck Millipore) and 0.4mM each of dNTP. PCR
conditions were: 2min at 94 C, followed by 30 cycles of 98 C for 10 s, 66 C for
60 s and 68 C for 10 s. The PCR product was puriﬁed from the band of a 0.8%
agarose gel (Seakem GTG Agarose, Lonza) with Illustra GFX PCR DNA and Gel
Band Puriﬁcation Kit, GE Healthcare. The puriﬁed product was used for kasA
automated sequencing (using the primers: Forward 1, cgaagattgagtcggagaac;
Reverse 1, cttccatatcggtccgactc; Forward 2, gtcaagatcggcggtcac; Reverse 2,
cagacttcggcgcgtaca; Forward 3, gtgatcggtctgcagcttg; Reverse 3, ctcctccgtctcgatgag;
Forward 4, ctcatcgagacggaggag; Reverse 4, cgttgggcatgatcatctg; Forward 5,
tgtacgcgccgaagtctg; Reverse 5, gatcccacttggtgacgaac). DNA sequencing reactions
were performed with a BigDye terminator V3.1 cycle sequencing kit (Applied
Biosystems).
Synthesis of FAMEs and MAMEs. The whole-cell effect of GSK3011724A was
studied by treating M. bovis BCG cultures (10ml) at an OD600nm of 0.4–0.6 with a
dose-dependent increase in drug for 20 h before labelling using 1 mCiml 1
[1-14C]sodium acetate (37MBq, PerkinElmer) for a further 24 h at 37 C. The total
FAMEs and MAMEs were extracted14,44. Brieﬂy, cells were pelleted and incubated
overnight in 2ml of 5% tetrabutylammonium hydroxide at 100 C. The following
day, 4ml of dichloromethane was added with 300 ml of iodomethane and 2ml of
water and mixed for 30min. The reaction was centrifuged and the upper aqueous
layer discarded. Water (3ml) was added to the lower organic layer, mixed and
centrifuged as before and repeated once more. The organic layer was evaporated to
dryness and the methyl esters re-dissolved in diethyl-ether (4ml) and transferred to
a fresh tube. The diethyl-ether was evaporated and 200ml of dichloromethane used
to re-dissolve the extracted methyl esters. The total FAMEs and MAMEs were
analysed by TLC, using equal counts (c.p.m.) and exposed to Kodak X-Omat ﬁlm.
Quantiﬁcation of labelled FAMEs and MAMEs was determined by excising spots
directly from the TLC plates and subjecting them to scintillation counting using
10ml of EcoScintA.
Extraction of cell wall-bound MAMEs and lipids. M. bovis BCG was drug-
treated and labelled as described above. The cell wall-bound MAMEs, apolar and
polar phospholipids were extracted and analysed44. Brieﬂy, the cell pellet was
extracted four times using 4ml of chloroform:methanol:water (10:10:3, v/v/v),
Figure 5 | Impact of resistance-conferring mutations on the KasA-GSK3011724A crystal structure and structural comparison of KasA with KasB and
FabH. (a) Mapping of residues where resistance mutations occur onto the dimeric KasA-GSK3011724A X-ray crystallographic complex. GSK3011724A
(green stick) marks the acyl channel, whereas TLM (magenta) from PDB entry 4C72 (ref. 25) marks the malonyl pocket. (b) Residues P201 and P206 that
confer resistance by direct interactions with GSK3011724A are shown, as are the proximity of other resistance positions visible. (c) A ribbon representation
of the open and closed forms of KasA with resistance mutations highlighted. The open KasA-GSK3011724A dimer is shown in yellow and blue (chain A,
B respectively). The apo, closed conformation (PDB entry 2WGD (ref. 26)) is shown in orange and purple. The HTH arm formed by a5–a6 and the a’2 from
its dimer partner move substantially on transition between the open and closed states. Residues within these two regions of movement where resistance
mutations are found are shown in stick format. GSK3011724A, PEG and other residues sensitive to resistance mutations are shown in line format.
(d) Surface around Chain A within KasA-GSK3011724A complex shown to illustrate the role of M277 in the open and closed states. Colouring and
representations identical to c. (e) Hydrogen bonding interactions around T114 within the open KasA-GSK3011724A complex. (f) Structural alignment of
KasA-GSK3011724A (yellow and blue) with KasB (PDB entry 2GP6 (ref. 54)) (magenta). The indazole ring of GSK3011724A sits favourably over G200 and
P201 in KasA. In KasB, the respective residues of T199 and R200 would not be able to accommodate this favourable binding mode. (g) Structural overlay of
KasA-GSK3011724A (yellow and blue) with FabH (PDB entry 2QNZ (ref. 55)) (orange). In FabH, T145 would directly clash with the indazole ring of
GSK3011724A, accounting for the compound selectivity for KasA.
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retaining the delipidated cell pellet (for analysis of cell wall-bound mycolic acids)
and collecting the solvent extract sequentially, which was combined and dried.
To the dried extract, 4ml of chloroform:methanol:water (10:10:3, v/v/v) was added,
followed by chloroform (1.75ml) and water (0.75ml), and the entire mixture
centrifuged and the lower organic layer recovered. The lower organic layer was
washed twice using chloroform:methanol:water (2ml, 3:47:48, v/v/v) and dried
to provide a total lipid extract, which was re-dissolved in chloroform:methanol
(2:1, v/v) and an aliquot subjected to scintillation counting using 10ml of EcoScintA.
The total lipid extract was further partitioned between the phases arising from
methanol:0.3% NaCl (2ml, 100:10, v/v) and 2ml of petroleum-ether (60–80 C).
The entire contents were mixed on a blood rotor, centrifuged and the upper layer
collected. The lower layer was re-extracted using 2ml of petroleum-ether
(60–80 C). The combined petroleum-ether layers were evaporated to afford the
crude apolar lipids. To the lower organic layer, 2.3ml of chloroform:methanol:0.3%
NaCl (50:100:40, v/v/v) was added, followed by 750ml of chloroform:methanol:0.3%
NaCl (50:100:40) and a further 1.3ml of chloroform and 1.3ml 0.3% NaCl. The
entire contents were mixed, centrifuged and the lower layer recovered and dried to
afford the crude polar lipids. The apolar and polar lipids were re-dissolved in
chloroform:methanol (2:1, v/v) and an aliquot subjected to scintillation counting
using 10ml of EcoScintA. The total lipid extracts and apolar/polar lipids were
analysed by TLC in the following solvent systems using equal counts (as stated)
before being exposed to Kodak X-Omat ﬁlm. Apolar lipids were resolved using
three solvent systems A: ﬁrst direction, petroleum-ether (60:80 C)):ethyl acetate
(98:2, v/v, thrice); second direction, petroleum-ether (60:80 C):acetone (98:2, v/v).
Solvent system B: ﬁrst direction, petroleum-ether (60:80 C):acetone (92:8, v/v,
thrice); second direction, toluene:acetone (95:5, v/v). Solvent system C: ﬁrst
direction, chloroform:methanol (96:4, v/v); second direction, toluene:acetone
(80:20, v/v). The polar lipids were analysed using chloroform:methanol:ammonium
hydroxide:water (65:25:0.5:3.6, v/v/v). The total lipid extract was analysed using
chloroform:methanol:concentrated ammonium hydroxide (80:20:2, v/v/v) to reveal
TDM and TMM. The recovered delipidated cells were used to analyse cell
wall-bound mycolic acids following release using 5% tetrabutylammonium
hydroxide at 100 C and methylation as described above for total FAMEs and
MAMEs. The recovered cell wall-bound MAMEs were analysed by TLC, using an
equal aliquot (5%) and exposed to Kodak X-Omat ﬁlm.
Original scans of all TLCs are shown in Supplementary Fig. 5.
KasA activity assay. Recombinant FabD, holo-AcpM and C16-AcpM were
overexpressed in C41 (DE3) Escherichia coli cells from pET28a-fabD and
pET28a-acpM and puriﬁed45. Brieﬂy, cells were resuspended in buffer (50mM
potassium phosphate, pH 7.5, 0.5M NaCl and 10mM (AcpM)/25mM (FabD)
imidazole) containing DNAse, Complete protease inhibitor-cocktail tablets (Roche)
and 0.1mgml 1 lysozyme. Cells were disrupted by 6 passes through a French
Press and the clariﬁed lysate was loaded onto a pre-equilibrated (with buffer)
Ni2þ -charged 1ml His-Trap column. A step gradient of imidazole (50–1,000mM)
was used to wash and elute the recombinant protein. Recombinant AcpM was
dialysed into 0.1M Tris pH 7.5, 500mM NaCl and loaded onto a column
containing 1ml Thiopropyl-Sepharose 6B. Acyl-AcpM was collected in the
ﬂow through. Holo-AcpM was eluted with an increasing concentration of
b-mercaptoethanol (5–100mM). All puriﬁed enzymes were dialysed ﬁrstly against
50mM Tris pH 7.5, 50mM NaCl, 10% (v/v) glycerol, 2mM EDTA and secondly
against the same buffer without EDTA.
The E. coli expression plasmid, pET28a-kasA (ref. 18), was transformed into
E. coli BL21 (DE3). A resulting single colony was used to inoculate an overnight
culture, which was subsequently used to inoculate 1 l LB broth, 1% (w/v) glucose,
50mgml 1 Kanamycin. The culture was incubated at 37 C, 180 rpm, until
OD600nm reached 0.4–0.6. The culture was cooled to 16 C and induced with 1mM
IPTG. Growth was continued for 20 h at 16 C, 180 r.p.m., and then the cells were
harvested by centrifugation. The cell pellet was resuspended in buffer (50mM
potassium phosphate, pH 7.45, 0.5M NaCl and 10mM imidazole) containing
DNAse, RNAse, Complete protease inhibitor-cocktail tablets (Roche) and
0.1mg.ml 1 lysozyme. Cells were disrupted by 6 passes through a French Press at
1 ksi and centrifuged at 15,000 r.p.m., 40min at 4 C. The supernatant was loaded
onto a pre-equilibrated (with buffer) Ni2þ -charged 1ml His-Trap column. The
column was washed extensively using buffer and the proteins were eluted with a
step-wise gradient of imidazole (50, 100, 150, 200, 350 and 500mM). SDS–PAGE
was used to detect the presence of puriﬁed KasA, which was dialysed against
50mM Tris.HCl, pH 7.5, 300mM NaCl, 10% (v/v) glycerol and stored at  20 C.
The assay for mycobacterial KasA activity was performed18. Assay components
were mixed together in a batch fashion, before equally dividing according to the
number of assays performed. The amounts stated correspond to a single reaction.
Holo-AcpM (40 mg), in 200mM potassium phosphate pH 7.0, 5mM
b-mercaptoethanol and a ﬁnal volume of 40 ml, was incubated on ice for 30min.
[2-14C]Malonyl-CoA (0.05 mCi, 1.85 kBq, PerkinElmer) and 50 ng FabD were
added and the reaction was incubated at 37 C for 1 h. 42.5 mg C16-Acpm:Holo-
AcpM mix (42.5 mg) was added with 200mM potassium phosphate and 5mM
b-mercaptoethanol to a ﬁnal volume of 89 ml. The reaction mix was aliquoted into
1.5ml microcentrifuge tubes, according to single assay conditions. An aliquot of
KasA (0.25 mg) (or replaced with an equal volume of buffer) was added and the
reactions were incubated at 37 C for 1.5 h. The reaction was quenched with 2ml of
freshly prepared reducing solution: 5mgml 1 NaBH4 in 0.1M K2HPO4, 0.4M
KCl, 30% (v/v) tetrahydrofuran. The reaction was incubated overnight at 37 C.
The reduced b-ketoacyl product was extracted twice using 2ml of water-saturated
toluene, and the combined organic phase washed thrice using 2ml of toluene-
saturated water. The organic layer was transferred to a scintillation vial and dried.
The radiolabelled product was quantiﬁed by liquid scintillation counting using
10ml of EcoScintA.
Chemoproteomics. The chemoproteomic inhibition binding experiments were
performed as previously described19,20. Brieﬂy, sepharose beads were derivatized
with 1, the GSK3011724A-tagged analogue, at 2mM compound concentration.
Beads were washed and equilibrated in lysis buffer (50mM Tris-HCl, pH 7.4, 0.4%
Igepal-CA630, 1.5mM MgCl2, 5% glycerol, 150mM NaCl, 25mM NaF, 1mM
Na3VO4, 1mM dithiothreitol (DTT) and one Complete EDTA-free protease
inhibitor tablet (Roche)). The equilibrated beads were incubated at 4 C for 1 h
either with 0.1ml (0.3mg) M. bovis BCG extract or with 1ml (5mg) mixed
HEK293/K562/Placenta extract, which was pre-incubated with compound or
DMSO (vehicle control). Beads were transferred either to Filter plates (Durapore
(PVDF membrane, Merck Millipore)) or to disposable columns (MoBiTec),
washed extensively with lysis buffer and eluted with SDS sample buffer. Proteins
were alkylated, separated on 4–12% Bis-Tris NuPAGE (Life technologies) and
stained with colloidal Coomassie. Gel lanes were cut into three slices and subjected
to in-gel digest using LysC for 2 h and trypsin overnight19. Digestion, labelling with
TMT isobaric mass tags, peptide fractionation and mass spectrometric analyses
were performed19,46. Proteins were quantiﬁed by isobaric mass tagging and
liquid chromatography-tandem mass spectrometry (LC-MS/MS). The
proteins.fasta ﬁle for M. bovis BCG was downloaded (11th May 2011) from
http://genome.tbdb.org/annotation/genome/tbdb/MultiDownloads.html and
supplemented with the sequences of bovine serum albumin, porcine trypsin and
mouse, rat, sheep and dog keratins. Decoy versions of all proteins were created and
added. The search database contained a total of 11,492 protein sequences, 50%
forward, 50% reverse. Protein identiﬁcation and quantiﬁcation was performed47.
Proteins identiﬁed with 41 unique peptide matches were considered for further
data analysis. Apparent dissociation constants were determined by taking into
account the protein depletion by the beads19. Raw data tables for the
chemoproteomics experiments can be found in the Supplementary Data 1–6.
TheM. bovis BCG extracts were prepared as follows:M. bovis BCG was cultured
in 7H9 medium without glycerol and supplemented with 2% (w/v) glucose and
0.025% (v/v) tyloxapol at 37 C for 8–10 days to reach an OD600nm of 0.8–1.0. The
culture was centrifuged and the pellet was washed with PBS and 0.025% (v/v)
tyloxapol. The pellet was resuspended in lysis buffer (0.4% (v/v) Igepal was
replaced with 0.8 (v/v)% NP40) and sonicated for three cycles at 50% amplitude for
30 s (Sonics-VibracellTM) in ice. This lysate was ultracentrifuged at 4 C for 60min
and the cellular debris was discarded.
KasA protein production and structure determination. The overexpression
plasmid, pET28a-kasA, was transformed into E. coli BL21 (DE3) cells. A single
colony was used to inoculate 100ml LB broth containing 50 mgml 1 Kanamycin
and 1% (v/v) glucose. Cells were cultured overnight at 30 C, 240 r.p.m. A 20 l
Biolafﬁte fermenter containing 15 l of Overnight Express Instant TB (Merck),
1% (v/v) glycerol, 50 mgml 1 Kanamycin and 20ml of antifoam (DC1520) was
inoculated with the overnight culture to 2% (v/v). The culture was grown at 37 C,
340 r.p.m., 12 lmin 1 air ﬂow. The fermenter was cooled to 25 C when the
OD600nm reached 2.4. The culture was incubated for 20 h before harvesting the
cells. The cell pellet was resuspended in 5ml g 1 cells in Buffer A (50mM Tris,
500mM NaCl, 10% (v/v) glycerol, 2mM DTT, pH 8.5, with 1mgml 1 lysozyme,
Protease inhibitor-cocktail set III (Sigma) and 10 ml Benzonase). The sample
was lysed by sonication on ice for 10min (10 s on, 10 s off). The lysate was
centrifuged at 18,000 r.p.m., 4 C for 30min. The supernatant was loaded onto a
pre-equilibrated Ni2þ -charged 10ml His-Trap column. The column was washed
back to baseline with Buffer A and the protein was eluted using a linear gradient
over 20 column volumes using Buffer B (Buffer A containing 500mM imidazole).
KasA was further puriﬁed by gel ﬁltration in Buffer A using a Superdex 200
column.
KasA was co-crystallized with GSK3011724A using protein at 10.6mgml 1
and ligand at a nominal concentration of 30mM in 100þ 100 nl sitting drops at
20 C. The well solution was 8% (w/w) isopropanol, 0.2M NaCl, 10mM tris(2-
carboxyethyl)phosphine (TCEP). Crystals were cryoprotected using 30% (v/v)
glycerol before ﬂash freezing in liquid nitrogen. Data from a single crystal was
collected at the Diamond Synchrotron Radiation Facility (i04) and processed in P31
to 2.13 Å using XDS (within AUTOPROC [Global Phasing Limited])48 and
AIMLESS49. A molecular replacement solution was determined with a previously
collected in house structure using Phaser50. The P31 cell (a¼ b¼ 90, g¼ 120,
a¼ b¼ 77.338Å, c¼ 147.675Å) has two molecules in the asymmetric unit that
form a dimer. Model building and reﬁnement of the KasA structures was carried
out using alternating rounds of COOT51 for manual model building and
REFMAC52 for maximum likelihood reﬁnement via CCP4 (ref. 53). As the data
was merohedrally twinned, TWIN reﬁnement within REFMAC was used, with the
reﬁned twin fraction being 39%. A clear difference in density for GSK3011724A,
and also for a PEG-like molecule was present in both chains in the dimer. Whilst
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PEG was not explicitly added to the wells, this was present in adjacent
crystallization conditions and we believe there may be trace PEG present.
Alternatively, the linear molecule may be residual lipid present in the protein,
although apo-structures do not contain this lipid and the protein is crystallized in
the closed conformation even in PEG conditions. A stereo diagram is displayed in
Supplementary Fig. 6. Statistics for the data collection and reﬁned co-ordinates are
given in Table 5.
Data availability. The atomic co-ordinates and structure factors reported in this
paper have been deposited in the Protein Data Bank with the code 5LD8. Data is
available upon request from the corresponding authors.
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